BIG DIWALI SALE - Flat 70% Discount On All Pendrive / Android Courses, Valid Till 30th Oct'19. For More Call On 9354229384, 9354252518, 9999830584, 8077211847.

Current Affairs

Cabinet approves India, US Inter-Institutional Agreement in medicine

Date: 18 July 2019 Tags: India & World

Union Cabinet has given ex-post facto approval to Inter-Institutional Agreement signed between India and United States (US) in the field of medicine including in areas of regenerative medicine and 3D bioprinting. The agreement was signed in December 2018 between Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Trivandrum (Institute of National Importance under Department of Science and Technology DST) and Wake Forest University Health Sciences on behalf of its Institute for Regenerative Medicine (WFIRM), North Carolina, US.

About Inter-Institutional Agreement

  • Objective:  Contribute towards development of research and education of both institutions through academic collaboration.
  • Features: It envisages contributions in areas of regenerative medicine and 3D bioprinting, new technologies, exchange of scientific ideas/information and technologies, and joint use of scientific infrastructure.
  • Collaboration areas: The general areas of common interest where collaboration and exchange of knowledge are intended includes (i) Exchange of faculty members and students for training, study and research especially in the areas on 3D Bioprinting (ii) Execution of joint research projects and (iii) Exchange of information and academic publications.
  • Benefits: It will enable signatory institutions to conduct joint research projects, training programmes, conferences, seminars etc. It will be open to all qualified scientists and technologists, and will be supported on basis of scientific merit and excellence. 
  • It will lead to the development of specific projects, each of which may have academic, clinical and commercial implications.
  • The scientific research and technology development conducted in the areas of regenerative medicine and 3D bio-printing will have potential for generation of new Intellectual Property (IP), processes, prototypes or products.